IS5542A - Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS) - Google Patents

Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS)

Info

Publication number
IS5542A
IS5542A IS5542A IS5542A IS5542A IS 5542 A IS5542 A IS 5542A IS 5542 A IS5542 A IS 5542A IS 5542 A IS5542 A IS 5542A IS 5542 A IS5542 A IS 5542A
Authority
IS
Iceland
Prior art keywords
cns
disorders
treatment
nervous system
central nervous
Prior art date
Application number
IS5542A
Other languages
English (en)
Inventor
Cox Brian
Patrick Healy Mark
Stuart Nobbs Malcolm
Punjabhai Shah Gita
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5542A publication Critical patent/IS5542A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5542A 1997-12-22 2000-06-20 Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS) IS5542A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds
PCT/EP1998/008273 WO1999032462A1 (en) 1997-12-22 1998-12-18 Triazine compounds for treatment of cns disorders

Publications (1)

Publication Number Publication Date
IS5542A true IS5542A (is) 2000-06-20

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5542A IS5542A (is) 1997-12-22 2000-06-20 Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS)

Country Status (34)

Country Link
US (2) US6265405B1 (is)
EP (1) EP1042304A1 (is)
JP (1) JP2001526275A (is)
KR (1) KR20010024800A (is)
CN (1) CN1284951A (is)
AP (1) AP2000001846A0 (is)
AR (1) AR014146A1 (is)
AU (1) AU753874B2 (is)
BR (1) BR9814495A (is)
CA (1) CA2315620A1 (is)
CO (1) CO5011066A1 (is)
EA (1) EA200000561A1 (is)
EE (1) EE200000391A (is)
GB (1) GB9726987D0 (is)
GT (1) GT199800203A (is)
HN (1) HN1998000193A (is)
HR (1) HRP20000419A2 (is)
HU (1) HUP0100611A3 (is)
ID (1) ID25449A (is)
IL (1) IL136867A0 (is)
IS (1) IS5542A (is)
JO (1) JO2065B1 (is)
MA (1) MA26587A1 (is)
NO (1) NO20003211L (is)
NZ (1) NZ505254A (is)
PA (1) PA8465101A1 (is)
PE (1) PE20000063A1 (is)
PL (1) PL341392A1 (is)
SK (1) SK9592000A3 (is)
SV (1) SV1998000151A (is)
TR (1) TR200001970T2 (is)
WO (1) WO1999032462A1 (is)
YU (1) YU39600A (is)
ZA (1) ZA9811725B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ES2286328T3 (es) * 2001-12-27 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Aroilpirrolheteroaril y metanoles utiles para tratar transtornos del sistema nervioso central.
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TWI704139B (zh) 2015-08-17 2020-09-11 日商日本煙草產業股份有限公司 羥基三化合物及其醫藥用途
EP3524605B1 (en) * 2018-02-13 2019-11-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. New efficient process for the preparation of sitagliptin
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
EP0021121B1 (en) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
IT1145308B (it) 1979-08-16 1986-11-05 Wellcome Found Composti aromatici sostituiti
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
AU688729B2 (en) 1992-06-12 1998-03-19 Wellcome Foundation Limited, The Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
JPH08504798A (ja) 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
NO20003211L (no) 2000-08-21
HUP0100611A2 (hu) 2001-09-28
US6265405B1 (en) 2001-07-24
AU2414799A (en) 1999-07-12
ZA9811725B (en) 2000-06-27
GT199800203A (es) 2000-06-14
SK9592000A3 (en) 2001-03-12
WO1999032462A1 (en) 1999-07-01
AR014146A1 (es) 2001-02-07
AP2000001846A0 (en) 2000-06-30
IL136867A0 (en) 2001-06-14
NZ505254A (en) 2002-06-28
GB9726987D0 (en) 1998-02-18
HN1998000193A (es) 2000-04-05
ID25449A (id) 2000-10-05
EA200000561A1 (ru) 2001-04-23
EE200000391A (et) 2002-02-15
SV1998000151A (es) 1999-07-05
NO20003211D0 (no) 2000-06-21
EP1042304A1 (en) 2000-10-11
CA2315620A1 (en) 1999-07-01
HRP20000419A2 (en) 2000-12-31
PA8465101A1 (es) 2000-09-29
AU753874B2 (en) 2002-10-31
TR200001970T2 (tr) 2001-01-22
CO5011066A1 (es) 2001-02-28
PE20000063A1 (es) 2000-02-16
US6465461B1 (en) 2002-10-15
MA26587A1 (fr) 2004-12-20
JO2065B1 (en) 2000-05-21
HUP0100611A3 (en) 2003-03-28
JP2001526275A (ja) 2001-12-18
CN1284951A (zh) 2001-02-21
YU39600A (sh) 2002-11-15
KR20010024800A (ko) 2001-03-26
BR9814495A (pt) 2000-10-10
PL341392A1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
DK0769947T3 (da) Indolinonforbindelser til behandling af sygdom
NO994689D0 (no) Fremgangsmaate til aa diagnostisere psykiatriske lidelser
NO972869D0 (no) Fremgangsmåte for fremstilling av höyrent melamin
IS5085A (is) Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
DK1053217T3 (da) Fremgangsmåde til fremstilling af n-propanol
NO20002951D0 (no) FremgangsmÕte til gjenvinning av olefiner
SI0908458T1 (sl) Substituirani piridilmetilpiperazinovi in piperidinovi derivati, njihova priprava in njihova uporaba za zdravljenje motenj centralnega zivcnega sistema (cns)
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
NO20012285D0 (no) Fremgangsmåte til fremstilling av rent melamin
DK1105390T3 (da) Imidazo(1,2a)pyridinderivater til behandling af gastrointestinale sygdomme
NO20000788D0 (no) Fremgangsmåte for fremstilling av aromatiske aminer
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DK1008558T3 (da) Fremgangsmåde til behandling af organisk spildevand
DK0912603T3 (da) Fremgangsmåde til fremstilling af visse azacyclohexapeptider
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK0975594T3 (da) Fremgangsmåde til fremstilling af indolderivater
HUP0004030A3 (en) Process for the purification of aspartame derivative
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
DK0842930T3 (da) Fremgangsmåde til syntese af benzothiophener
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser